Search

Your search keyword '"Gramenzi, A"' showing total 99 results
Start Over Author "Gramenzi, A" Journal journal of hepatology
99 results on '"Gramenzi, A"'

3. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre study

Author

Vitale A, Burra P, Frigo AC, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Rapaccini GL, Di Marco M, Caturelli E, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U, Italian Liver Cancer group, TREVISANI, FRANCO, PISCAGLIA, FABIO, ZOLI, MARCO, BERNARDI, MAURO, BOLONDI, LUIGI, BISELLI, MAURIZIO, CARACENI, PAOLO, CUCCHETTI, ALESSANDRO, DOMENICALI, MARCO, GRAMENZI, ANNAGIULIA, Vitale, A., Burra, P., Frigo, A. C., Trevisani, F., Farinati, F., Spolverato, G., Volk, M., Giannini, E. G., Ciccarese, F., Piscaglia, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Cabibbo, G., Felder, M., Gasbarrini, A., Sacco, R., Foschi, F. G., Missale, G., Morisco, F., Svegliati Baroni, G., Virdone, R., Cillo, U, Olmi, S, on behalf of Italian Liver Cancer, (ITA. LI. CA) group., Vitale, Alessandro, Burra, Patrizia, Frigo, Anna Chiara, Trevisani, Franco, Farinati, Fabio, Spolverato, Gaya, Volk, Michael, Giannini, Edoardo G, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Gasbarrini, Antonio, Sacco, Rodolfo, Foschi, Francesco Giuseppe, Missale, Gabriele, Morisco, Filomena, Svegliati Baroni, Gianluca, Virdone, Roberto, Cillo, Umberto, Guarino, Maria, Vitale A, Burra P, Frigo AC, Trevisani F, Farinati F, Spolverato G, Volk M, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Cillo U, Italian Liver Cancer (ITA.LI.CA) group, Bernardi M, Bolondi L, Biselli M, Caraceni P, Cucchetti A, Domenicali M, and Gramenzi A

Subjects
Male, medicine.medical_specialty, Cirrhosis, Carcinoma, Hepatocellular, Loco-regional therapie, Hepatocellular carcinoma, Settore MED/12 - GASTROENTEROLOGIA, Hepatitis C virus, Kaplan-Meier Estimate, medicine.disease_cause, Gastroenterology, Cohort Studies, Liver disease, Interquartile range, Internal medicine, medicine, Humans, Best supportive care, Liver resection, Loco-regional therapies, Survival benefit, Aged, Female, Italy, Liver Neoplasms, Middle Aged, Multivariate Analysis, Neoplasm Staging, Prognosis, Treatment Outcome, Medicine (all), Hepatology, BEST SUPPORTING CARE, Cirrhosi, Performance status, business.industry, CIRRHOISIS, Carcinoma, Hepatocellular, medicine.disease, BCLC Stage, Liver cancer, business
Abstract

Background & Aims The role of hepatic resection for hepatocellular carcinoma (HCC) in different Barcelona Clinic Liver Cancer (BCLC) stages is controversial. We aimed at measuring the survival benefit of resection vs. non-surgical-therapies in each BCLC stage. Methods Using the ITA.LI.CA database, we identified 2090 BCLC A, B, and C HCC patients observed between 2000 and 2012: 550 underwent resection, 1046 loco-regional therapy (LRT), and 494 best supportive care (BSC). A multivariate log-logistic model was chosen to predict median survival (MS) after resection vs. MS after LRT or BSC. The results were expressed as net survival benefit of resection: (MS resection - MS LRT)/MS BSC. Results After stratifying for BCLC stage, the median net survival benefit of resection over LRT was: BCLC 0 = 62% (40%, 82%), A = 45% (13%, 65%), B = 46% (9%, 76%), C = -16% (-55%, 33%). Model for end-stage liver disease (MELD) score >9, Child B class, and performance status (PST) = 2 were the main risk factors for liver resection. 1181 Child A patients (57%) with MELD ≤9 and PST 9 or PST = 2 or Child B class), resection did not prove any survival benefit over LRT. Conclusions Resection could result in survival benefit over LRT for HCC patients regardless of their BCLC stage, provided that liver dysfunction (Child B or MELD >9) and PST >1 are absent.

Published
2014

4. 466 NATREMIA AND CHILD-TURCOTTE-PUGH (CTP) SCORE MAY IMPROVE THE SELECTION OF CANDIDATES FOR LIVER TRANSPLANTATION (LT) WITH LOW MODEL FOR END-STAGE LIVER DISEASE SCORE (MELD)

Author

S. Gitto, M. Biselli, A. Gramenzi, G. Vitale, S. Lorenzini, R. Di Donato, L. Brodosi, M.C. Morelli, G.L. Grazi, A.D. Pinna, M. Bernardi, P. Andreone, and Bologna Liver Transplantation Group (BLTG)

Subjects
medicine.medical_specialty, Model for End-Stage Liver Disease, Hepatology, business.industry, medicine.medical_treatment, Internal medicine, medicine, Liver transplantation, business, Gastroenterology, Selection (genetic algorithm), Child turcotte pugh, Surgery
Published
2009
Full Text
View/download PDF

5. Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial

Author

Loriana Di Giammarino, Antonia D'Errico, Giovanni Gasbarrini, Pietro Andreone, Mauro Bernardi, Carmela Cursaro, Annagiulia Gramenzi, Giorgio Sbolli, Sirio Fiorino, and Rita Miniero

Subjects
Male, medicine.medical_specialty, Combination therapy, Genotype, medicine.medical_treatment, Biopsy, Alpha interferon, Hepacivirus, Gastroenterology, Antiviral Agents, chemistry.chemical_compound, Necrosis, Liver Function Tests, Interferon, Multicenter trial, Internal medicine, Ribavirin, medicine, Humans, Treatment Failure, Interferon alfa, Inflammation, Chemotherapy, Hepatology, business.industry, Interferon-alpha, Drug Resistance, Microbial, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, chemistry, Immunology, Drug Therapy, Combination, Female, business, medicine.drug
Abstract

Background/Aims: Interferon-α plus ribavirin seem to be more efficacious than interferon monotherapy in chronic hepatitis C. In a multicenter randomized trial, we evaluated the efficacy of this association for interferon-α resistant chronic hepatitis C. Methods: Fifty patients who were non-responders to recombinant or lymphoblastoid interferon-α were randomized to receive either ribavirin (800 mg/day) plus leucocytic interferon-α (3 mega units thrice weekly) or the same dose of interferon-α alone, for 6 months. Effects of therapy were evaluated by serum aminotransferase and hepatitis C virus RNA levels and control liver biopsies. Results: At the end of treatment, aminotransferase levels become normal in 9/26 patients receiving combination therapy (35% [confidence interval, 16% to 53%]) and in 2/24 receiving interferon-α alone (8% [confidence interval, −3% to 19%]) ( p =0.03). Aminotransferase normalization was never associated with hepatitis C virus RNA clearance. All patients with normal aminotransferase relapsed after discontinuation of therapy. At the end of treatment, mean hepatitis C virus RNA levels significantly decreased only in the group receiving combination therapy, but returned to pretreatment values 6 months thereafter. No histological improvement was observed in either group. Conclusions: There is no indication for treatment with interferon-α at the dose of 3 mega units thrice weekly plus 800 mg/day of ribavirin for 6 months in chronic hepatitis C resistant to interferon-α.

Published
1999

7. 148 LIVER TRANSPLANTATION IN CIRRHOTIC PATIENTS WITH MELD SCORE 18: A NEW PROGNOSTIC MODEL TO PREDICT DROP-OUT FROM THE WAITING LIST

Author

Dall'Agata, M., primary, Biselli, M., additional, Gramenzi, A., additional, Gitto, S., additional, Liberati, C., additional, Ravaioli, M., additional, Gambato, M., additional, Montalti, R., additional, Burra, P., additional, Cillo, U., additional, Gerunda, G.E., additional, Pinna, A.D., additional, Andreone, P., additional, and Bernardi, M., additional

Published
2013
Full Text
View/download PDF

8. 148 LIVER TRANSPLANTATION IN CIRRHOTIC PATIENTS WITH MELD SCORE 18: A NEW PROGNOSTIC MODEL TO PREDICT DROP-OUT FROM THE WAITING LIST

Author

C. Liberati, Roberto Montalti, Patrizia Burra, M. Dall'Agata, Matteo Ravaioli, Pietro Andreone, Maurizio Biselli, A. Gramenzi, Stefano Gitto, Giorgio Enrico Gerunda, U. Cillo, Martina Gambato, A.D. Pinna, and Mauro Bernardi

Subjects
medicine.medical_specialty, Hepatology, Waiting list, business.industry, medicine.medical_treatment, Internal medicine, Drop out, General surgery, medicine, Prognostic model, Liver transplantation, business, Gastroenterology
Abstract

148 LIVER TRANSPLANTATION IN CIRRHOTIC PATIENTS WITH MELD SCORE

Published
2013
Full Text
View/download PDF

9. Indomethacin enhances serum 2'5'-oligoadenylate synthetase in patients with hepatitis B and C virus chronic active hepatitis

Author

Andrea Buzzi, Giovanni Gasbarrini, Rita Miniero, Pietro Andreone, Carmela Cursaro, Giuseppe Sprovieri, and Annagiulia Gramenzi

Subjects
Adult, Male, Adolescent, Hepatitis C virus, Indomethacin, Alpha interferon, Pharmacology, medicine.disease_cause, Interferon, medicine, 2',5'-Oligoadenylate Synthetase, Humans, Hepatitis Antibodies, Hepatitis B e Antigens, Interferon alfa, Hepatitis, Chronic, Hepatitis, Hepatology, business.industry, Osmolar Concentration, Interferon-alpha, Hepatitis B, Middle Aged, medicine.disease, Hepatitis C, Drug Combinations, HBeAg, Immunology, Female, Viral hepatitis, business, medicine.drug
Abstract

Activation of the arachidonic acid metabolism seems to be one of the post-receptor mechanisms by which interferon- α induces antiviral protein synthesis. In this study, we evaluated the changes on serum 2′5′-oligoadenylate synthetase levels induced by acute administration of interferon- α , indomethacin and interferon- α plus indomethacin in 21 patients with hepatitis B or C virus chronic active hepatitis. Serum samples for 2′5′-oligoadenylate synthetase determination were collected in basal conditions and 8 h after the administration of interferon- α , indomethacin and interferon- α plus indomethacin. Compared to control value (mean±SE) (40.2±7.9 pg/dl) serum 2′5′-oligoadenylate synthetase concentration was significantly increased 1.5-fold after interferon- α (63.4±11, p p α plus indomethacin (148.9±25.1, p α caused a 1.5-fold increase in HBeAg- and hepatitis C virus-positive and a 2-fold increase in HBeAb-positive patients. Indomethacin led to a 1.8-fold increase in HBeAg, a 2-fold increase in hepatitis C virus-positive and surprisingly a 6.8-fold increase in HBeAb-positive patients. Simultaneous administration of the two drugs had an additive effect on the 2′5′-oligoadenylate synthetase increase in HBeAg-positive (2.4-fold increase) and a synergistic effect in hepatitis C virus- and HBeAb-positive patients (2.7- and 10.2-fold increase, respectively). Apart from confirming the interaction between arachidonic acid metabolites and interferon- α , the results of this study suggest both an altered antiviral response to interferon- α in viral chronic active hepatitis and the possibility that nonsteroid anti-inflammatory drugs can enhance the antiviral activity of interferon- α . We conclude that the association of interferon- α with nonsteroid anti-inflammatory drugs in patients with chronic viral hepatitis, who are non-responders to interferon- α alone, should be evaluated, taking into account the possible side effects of nonsteroid anti-inflammatory drugs.

Published
1994

10. Transcatheter arterial chemoembolization therapy (TACE) for patients with hepatocellular carcinoma (HCC): a comparative study using a matched untreated cohort

Author

Salvatore Ricca Rossellini, Carmela Cursaro, Franco Trevisani, Mauro Bernardi, Maurizio Biselli, Pietro Andreone, Giuseppe Francesco Stefanini, Annagiulia Gramenzi, and Cristina Rossi

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Hepatocellular carcinoma, Cohort, Medicine, business, medicine.disease, Transcatheter arterial chemoembolization, Gastroenterology
Published
2002
Full Text
View/download PDF

11. 811 A MODIFIED CHILD-TURCOTTE-PUGH (CTP) FOR SELECTION OF PATIENTS AFFECTED BY CIRRHOSIS CANDIDATES TO LIVER TRANSPLANTATION (LT) WITH LOW MODEL FOR END-STAGE LIVER DISEASE SCORE (MELD)

Author

Gitto, S., primary, Biselli, M., additional, Gramenzi, A., additional, Brodosi, L., additional, Di Donato, R., additional, Vitale, G., additional, Lorenzini, S., additional, Ravaioli, M., additional, Grazi, G.L., additional, Pinna, A.D., additional, Bernardi, M., additional, and Andreone, P., additional

Published
2010
Full Text
View/download PDF

13. 466 NATREMIA AND CHILD-TURCOTTE-PUGH (CTP) SCORE MAY IMPROVE THE SELECTION OF CANDIDATES FOR LIVER TRANSPLANTATION (LT) WITH LOW MODEL FOR END-STAGE LIVER DISEASE SCORE (MELD)

Author

Gitto, S., primary, Biselli, M., additional, Gramenzi, A., additional, Vitale, G., additional, Lorenzini, S., additional, Di Donato, R., additional, Brodosi, L., additional, Morelli, M.C., additional, Grazi, G.L., additional, Pinna, A.D., additional, Bernardi, M., additional, Andreone, P., additional, and Liver Transplantation Group (BLTG), Bologna, additional

Published
2009
Full Text
View/download PDF

14. 603 A MULTICENTER ITALIAN CROSS-SECTIONAL STUDY IN ELDERLY PATIENTS WITH HEPATITIS C VIRUS (HCV) INFECTION

Author

Conti, F., primary, Morieri, M.L., additional, Gramenzi, A., additional, Cammá, C., additional, Grieco, A., additional, Picciotto, A., additional, Taliani, G., additional, Romagno, D., additional, Costa, P., additional, Rendina, M., additional, Ancarani, F., additional, Chiaramonte, M., additional, Verucchi, G., additional, Craxì, A., additional, Bernardi, M., additional, and Andreone, P., additional

Published
2009
Full Text
View/download PDF

16. 811 A MODIFIED CHILD-TURCOTTE-PUGH (CTP) FOR SELECTION OF PATIENTS AFFECTED BY CIRRHOSIS CANDIDATES TO LIVER TRANSPLANTATION (LT) WITH LOW MODEL FOR END-STAGE LIVER DISEASE SCORE (MELD)

Author

S. Lorenzini, R. Di Donato, G.L. Grazi, P. Andreone, A.D. Pinna, Stefano Gitto, Maurizio Biselli, Mauro Bernardi, Giovanni Vitale, Matteo Ravaioli, Lucia Brodosi, and A. Gramenzi

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, medicine.medical_treatment, Liver transplantation, medicine.disease, Gastroenterology, Surgery, Model for End-Stage Liver Disease, Internal medicine, medicine, business, Selection (genetic algorithm), Child turcotte pugh
Published
2010
Full Text
View/download PDF

19. 603 A MULTICENTER ITALIAN CROSS-SECTIONAL STUDY IN ELDERLY PATIENTS WITH HEPATITIS C VIRUS (HCV) INFECTION

Author

F. Ancarani, Gloria Taliani, Gabriella Verucchi, C. Cammà, Fabio Conti, P. Costa, M.L. Morieri, P. Andreone, Mauro Bernardi, Maria Chiaramonte, Antonio Picciotto, Maria Rendina, A. Gramenzi, Antonio Craxì, A. Grieco, and D. Romagno

Subjects
medicine.medical_specialty, Hepatology, Cross-sectional study, business.industry, Internal medicine, Hepatitis C virus, medicine, medicine.disease_cause, business
Published
2009
Full Text
View/download PDF

20. [274] SURVEILLANCE FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA: IS IT EFFECTIVE IN INTERMEDIATE/ADVANCED CIRRHOSIS?

Author

Santi, V., primary, Trevisani, F., additional, Gramenzi, A., additional, Casadio, R., additional, Di Nolfo, M.A., additional, Del Poggio, P., additional, Benvegnu, L., additional, Rapaccini, G., additional, Farinati, F., additional, Zoli, M., additional, Borzio, F., additional, Giannini, E.G., additional, Caturelli, E., additional, and Bernard, M., additional

Published
2007
Full Text
View/download PDF

21. [611] KETOPROFEN PLUS PEG-IFN ALPHA-2a AND RIBAVIRIN AS A TRIPLE TREATMENT FOR GENOTYPE 1 (G1) CHRONIC HEPATITIS C (CHC): RESULTS OF A PHASE II RANDOMIZED CONTROLLED TRIAL

Author

Gramenzi, A., primary, Margotti, M., additional, Balsano, C., additional, Anticoli, S., additional, Cursaro, C., additional, Loggi, E., additional, Focetola, F., additional, Galli, S., additional, Furlini, G., additional, Bernard, M., additional, and Andreone, P., additional

Published
2007
Full Text
View/download PDF

23. 122 Hematopoietic stem cell mobilization in patients undergoing liver transplant or liver resection

Author

Loggi, E., primary, Gramenzi, A., additional, Talarico, S., additional, Catani, L., additional, Grazi, G.L., additional, Baccarani, U., additional, Fogli, M., additional, Vetrone, G., additional, Aluigi, M., additional, Marzocchi, G., additional, Lorenzini, S., additional, Bernardi, M., additional, Pinna, A.D., additional, Bresadola, F., additional, Baccarani, M., additional, Lemoli, R.M., additional, and Andreone, P., additional

Published
2006
Full Text
View/download PDF

24. 702 HEPATITIS B SURFACE ANTIGEN SERUM LEVELS AND SPECIFIC T CELLS RESPONSE IMPROVE THE MONITORING OF NUCLEOSIDE ANALOGUES TREATMENT IN HBEAG-NEGATIVE CHRONIC HEPATITIS B

Author

Elisabetta Loggi, L. Micco, F. Cannoletta, Silvia Galli, A. Gramenzi, Carmela Cursaro, Sirio Fiorino, Mauro Bernardi, P. Andreone, and Florian Bihl

Subjects
medicine.medical_specialty, Hepatology, business.industry, University hospital, Hepatitis b surface antigen, Virology, Hbeag negative, Chronic hepatitis, Microbiology section, Internal medicine, medicine, business, Nucleoside
Abstract

L. Micco1, A. Gramenzi1, E. Loggi1, S. Galli2, C. Cursaro1, F. Cannoletta1, S. Fiorino1, F. Bihl3, M. Bernardi1, P. Andreone1. 1Department of Internal Medicine, Cardioangiology and Hepatology, University of Bologna, Bologna, 2Department of Clinical and Experimental Medicine, Microbiology Section, University of Bologna, Bologna, Italy; 3Division of Gastroenterology and Hepatology, University Hospital of Geneva, Geneva, Switzerland E-mail: lorenzomicco@gmail.com

Published
2008
Full Text
View/download PDF

25. 217 G-CSF ADMINISTRATION IS NOT RELATED TO PEG-IFN ALFA-2B TREATMENT DURATION NOR RESPONSE IN LIVER TRANSPLANTED PATIENTS WITH HCV RECURRENCE

Author

Antonio Daniele Pinna, Francesco Azzaroli, Sonia Berardi, Enrico Roda, Pietro Andreone, Annagiulia Gramenzi, Francesca Lodato, Davide Festi, Giuseppe Mazzella, Mariarosa Tamè, and M. Di Girolamo

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Treatment duration, PEG-IFN alfa-2b, Hcv recurrence, Hepatitis C, Neutropenia, medicine.disease, Gastroenterology, Transplantation, chemistry.chemical_compound, chemistry, Interferon, Internal medicine, Medicine, business, medicine.drug
Published
2008
Full Text
View/download PDF

26. [611] KETOPROFEN PLUS PEG-IFN ALPHA-2a AND RIBAVIRIN AS A TRIPLE TREATMENT FOR GENOTYPE 1 (G1) CHRONIC HEPATITIS C (CHC): RESULTS OF A PHASE II RANDOMIZED CONTROLLED TRIAL

Author

Silvia Galli, S. Anticoli, M. Bernard, Elisabetta Loggi, Clara Balsano, F. Focetola, Pietro Andreone, Carmela Cursaro, Giuliano Furlini, Marzia Margotti, and Annagiulia Gramenzi

Subjects
Ketoprofen, medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Gastroenterology, law.invention, chemistry.chemical_compound, chemistry, Chronic hepatitis, Randomized controlled trial, law, Internal medicine, Genotype, medicine, PEG-IFN alpha-2A, business, medicine.drug
Published
2007
Full Text
View/download PDF

27. [274] SURVEILLANCE FOR EARLY DIAGNOSIS OF HEPATOCELLULAR CARCINOMA: IS IT EFFECTIVE IN INTERMEDIATE/ADVANCED CIRRHOSIS?

Author

V. Santi, L. Benvegnù, Eugenio Caturelli, R. Casadio, A. Gramenzi, M.A. Di Nolfo, Franco Borzio, Fabio Farinati, E.G. Giannini, G.L. Rapaccini, P. Del Poggio, M. Bernard, Marco Zoli, and Franco Trevisani

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Advanced cirrhosis, Hepatocellular carcinoma, Internal medicine, medicine, medicine.disease, business
Published
2007
Full Text
View/download PDF

28. 145 Outcome of liver transplant for alcoholic liver disease

Author

Lorenzini, S., primary, Biselli, M., additional, Gramenzi, A., additional, Del Gaudio, M., additional, Ravaioli, M., additional, Bollino, F., additional, Porzio, F., additional, Cursaro, C., additional, Grazi, G.L., additional, Bernardi, M., additional, and Andreone, P., additional

Published
2004
Full Text
View/download PDF

30. 122 Hematopoietic stem cell mobilization in patients undergoing liver transplant or liver resection

Author

A.D. Pinna, Roberto M. Lemoli, Michela Aluigi, M. Fogli, Umberto Baccarani, F. Bresadola, Mauro Bernardi, Michele Baccarani, S. Talarico, Elisabetta Loggi, Lucia Catani, Gaetano Vetrone, G. Marzocchi, Annagiulia Gramenzi, Stefania Lorenzini, Pietro Andreone, and Gian Luca Grazi

Subjects
medicine.medical_specialty, Hepatology, business.industry, Medicine, In patient, business, Hematopoietic Stem Cell Mobilization, Resection, Surgery
Published
2006
Full Text
View/download PDF

31. IFN plus ribavirin and amantadine for IFN-insensitive patients with chronic hepatitis C: Results of a multicenter, randomized, controlled trial

Author

Andreone, P., primary, Gramenzi, A., additional, Cursaro, C., additional, Pirraglia, C., additional, Verrucchi, G., additional, Attard, L., additional, Boccia, S., additional, Giacomoni, P.L., additional, Felline, F., additional, Biselli, M., additional, Loggi, E., additional, Lorenzini, S., additional, and Bernardi, M., additional

Published
2003
Full Text
View/download PDF

32. Combination treatment of post-transplant lymphoproliferative disorders (PTLDs) in liver transplant (OLT) recipients

Author

Andreone, Pietro, primary, Lorenzini, Stefania, additional, Gramenzi, Annagiulia, additional, Rondelli, Damiano, additional, Morelli, Cristina, additional, Grazi, Gian Luca, additional, Cursaro, Carmela, additional, Biselli, Maurizio, additional, Porzio, Federica, additional, Tura, Sante, additional, Baccarani, Michele, additional, Cavallari, Antonino, additional, and Bernardi, Mauro, additional

Published
2002
Full Text
View/download PDF

33. Transcatheter arterial chemoembolization therapy (TACE) for patients with hepatocellular carcinoma (HCC): a comparative study using a matched untreated cohort

Author

Biselli, Maurizio, primary, Gramenzi, Annagiulia, additional, Cursaro, Carmela, additional, Rossellini, Salvatore Ricca, additional, Rossi, Cristina, additional, Stefanini, Giuseppe Francesco, additional, Trevisani, Franco, additional, Bernardi, Mauro, additional, and Andreone, Pietro, additional

Published
2002
Full Text
View/download PDF

34. 489 Pegylated interferon plus ribavirin for the treatment of recurrent HCV infection after liver transplantation

Author

A. Gramenzi, F. Bollino, P. Andreone, Carmela Cursaro, Maurizio Biselli, Mauro Bernardi, and S. Lorenzini

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, medicine.medical_treatment, Liver transplantation, Gastroenterology, chemistry.chemical_compound, chemistry, Pegylated interferon, Internal medicine, medicine, business, medicine.drug
Published
2004
Full Text
View/download PDF

35. 145 Outcome of liver transplant for alcoholic liver disease

Author

G.L. Grazi, Federica Porzio, S. Lorenzini, Maurizio Biselli, P. Andreone, F. Bollino, Matteo Ravaioli, Mauro Bernardi, A. Gramenzi, Carmela Cursaro, and M. Del Gaudio

Subjects
Alcoholic liver disease, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, medicine, medicine.disease, business, Outcome (game theory), Gastroenterology
Published
2004
Full Text
View/download PDF

37. IFN plus ribavirin and amantadine for IFN-insensitive patients with chronic hepatitis C: Results of a multicenter, randomized, controlled trial

Author

Stefania Lorenzini, F. Felline, Luciano Attard, C. Pirraglia, P. Andreone, Elisabetta Loggi, Maurizio Biselli, Carmela Cursaro, P. Giacomoni, G. Verrucchi, Mauro Bernardi, S. Boccia, and A. Gramenzi

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Amantadine, Gastroenterology, law.invention, chemistry.chemical_compound, Chronic hepatitis, chemistry, Randomized controlled trial, law, Internal medicine, medicine, business, medicine.drug
Published
2003
Full Text
View/download PDF

39. Lamivudine (LAM) plus HBIg combination therapy compared to HBIg or notherapy in preventing hepatitis B (HBV) recurrence after livertransplantation (LT)

Author

Andreone, P., primary, Grazi, G.L., additional, Gramenzi, A., additional, Cursaro, C., additional, Biselli, M., additional, Caraceni, P., additional, Morelli, M.C., additional, Sama, C., additional, Iovine, E., additional, Del Gaudio, M., additional, Bellusci, R., additional, Mazziotti, A., additional, Cavallari, A., additional, and Bernardi, M., additional

Published
2000
Full Text
View/download PDF

42. High dose of interferonα (IFN) plus ribavirin (RIBA) for 6 or 12 months in non responder (NR) patients with chronic hepatitis C (CHC): Results of a randomized trial

Author

Andreone, P., primary, Cursaro, C., additional, Gramenzi, A., additional, Margotti, M., additional, Ferri, E., additional, Talarico, S., additional, Di Giammarino, L., additional, Carella, R., additional, D'Errico, A., additional, Spinosa, M., additional, Spagnuolo, P., additional, and Bernardi, M., additional

Published
2000
Full Text
View/download PDF

43. Combination treatment of post-transplant lymphoproliferative disorders (PTLDs) in liver transplant (OLT) recipients

Author

Damiano Rondelli, Sante Tura, Michele Baccarani, Antonino Cavallari, Federica Porzio, Annagiulia Gramenzi, Carmela Cursaro, C. Morelli, Maurizio Biselli, Mauro Bernardi, Stefania Lorenzini, Pietro Andreone, and Gian Luca Grazi

Subjects
medicine.medical_specialty, Combined treatment, Hepatology, business.industry, Internal medicine, medicine, Lymphoproliferative disorders, business, medicine.disease, Gastroenterology, Post transplant
Published
2002
Full Text
View/download PDF

44. Outcome of patients with HBeAG negative hepatitis B awaiting liver transplantation (OLT) treated with lamivudine

Author

Carmela Cursaro, S. Romano, A. Gramenzi, Maurizio Biselli, H. Munira, P. Andreone, Mauro Bernardi, and Anna S.F. Lok

Subjects
medicine.medical_specialty, Hepatology, business.industry, medicine.medical_treatment, Lamivudine, Hepatitis B, Liver transplantation, medicine.disease, Gastroenterology, Hbeag negative, Internal medicine, Medicine, business, medicine.drug
Published
2001
Full Text
View/download PDF

45. Lamivudine (LAM) plus HBIg combination therapy compared to HBIg or notherapy in preventing hepatitis B (HBV) recurrence after livertransplantation (LT)

Author

Claudia Sama, Maurizio Biselli, Carmela Cursaro, M.C. Morelli, A. Gramenzi, G.L. Grazi, M. Del Gaudio, Antonino Cavallari, E. Iovine, Paolo Caraceni, P. Andreone, A. Mazziotti, R. Bellusci, and Mauro Bernardi

Subjects
medicine.medical_specialty, Hepatology, Combination therapy, business.industry, Internal medicine, Medicine, Lamivudine, Hepatitis B, business, medicine.disease, Gastroenterology, medicine.drug
Published
2000
Full Text
View/download PDF

47. High dose of interferonα (IFN) plus ribavirin (RIBA) for 6 or 12 months in non responder (NR) patients with chronic hepatitis C (CHC): Results of a randomized trial

Author

S. Talarico, R. Carella, L. Di Giammarino, P. Andreone, Marzia Margotti, M. Spinosa, A. Gramenzi, Antonietta D'Errico, Mauro Bernardi, E. Ferri, Carmela Cursaro, and P. Spagnuolo

Subjects
medicine.medical_specialty, Hepatology, business.industry, Ribavirin, Gastroenterology, law.invention, chemistry.chemical_compound, chemistry, Chronic hepatitis, Randomized controlled trial, law, Internal medicine, Physical therapy, Medicine, business
Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results